From Symptoms to Strategy: Testing as a Clinical Tool in COVID-19 Management
In this video, PA Yoke explains why testing is a critical clinical tool in managing COVID-19. She highlights how accurate diagnosis helps guide treatment decisions, informs patient choices about preventing transmission, and supports public health monitoring. PA Yoke also explores the complexity of identifying post-COVID conditions, including the wide range of symptoms and risk factors. She emphasizes that timely testing and diagnosis not only aid individual care but also contribute to a broader understanding of COVID’s long-term impacts.
Key Takeaways:
- Testing for COVID-19 remains important from both a treatment and public health perspective.
- Post-COVID conditions can impact anyone, but risk is higher in certain populations.
- COVID-19 infection can impact multiple organ systems, resulting in highly variable post-COVID conditions.
Speaker
Click on the photo below to learn more about the speaker.
References and Additional Resources:
CDC. CDC Science and the Public Health Approach to Long COVID. Published July 24, 2025. Accessed August 11, 2025. https://www.cdc.gov/long-covid/php/scientific-approach/index.html
COVID-19 – Global Situation. Who.int. Published May 28, 2025. Accessed August 11, 2025. https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON572
Deitelzweig S, Luo X, Nguyen JL, et al. Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. J Thromb Thrombolysis. 2022;53(4):766-776. doi:10.1007/s11239-022-02644-2
Lim SH, Ju HJ, Han JH, et al. Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw Open. 2023;6(10):e2336120. doi:10.1001/jamanetworkopen.2023.36120
Long COVID (Post-COVID Conditions, PCC). Yale Medicine. Published February 11, 2025. Accessed August 11, 2025. https://www.yalemedicine.org/conditions/long-covid-post-covid-conditions-pcc
Meng M, Wei R, Wu Y, et al. Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study. EClinicalMedicine. 2024;69(102500):102500. doi:10.1016/j.eclinm.2024.102500
Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. JAMA Netw Open. 2021;4(3):e211095. doi:10.1001/jamanetworkopen.2021.1095
Patel N, Dahman B, Bajaj JS. Development of new mental and physical health sequelae among US veterans after COVID-19. J Clin Med. 2022;11(12):3390. doi:10.3390/jcm11123390
Salah HM, Fudim M, O’Neil ST, Manna A, Chute CG, Caughey MC. Post-recovery COVID-19 and incident heart failure in the National COVID Cohort Collaborative (N3C) study. Nat Commun. 2022;13(1):4117. doi:10.1038/s41467-022-31834-y
Tesch F, Ehm F, Vivirito A, et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol. 2023;42(10):2905-2914. doi:10.1007/s10067-023-06670-0
Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311-321. doi:10.1016/S2213-8587(22)00044-4
Zhang J, Shu T, Zhu R, Yang F, Zhang B, Lai X. The long-term effect of COVID-19 disease severity on risk of diabetes incidence and the near 1-year follow-up outcomes among postdischarge patients in Wuhan. J Clin Med. 2022;11(11):3094. doi:10.3390/jcm11113094
Zhang V, Fisher M, Hou W, Zhang L, Duong TQ. Incidence of new-onset hypertension post-COVID-19: Comparison with influenza. Hypertension. 2023;80(10):2135-2148. doi:10.1161/HYPERTENSIONAHA.123.21174
Supported by
